![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Japanese Drugmaker’s ALS Candidate Shines in Phase 3
Japanese Drugmaker’s ALS Candidate Shines in Phase 3
Japanese drugmaker Mitsubishi Tanabe Pharma says a candidate for Lou Gehrig’s disease hit its target in a Phase 3 trial.
The trial showed that MCI-186 met its primary efficacy endpoint of mean change in amyotrophic lateral sclerosis patient performance on the ALS Functional Rating after 24 weeks of treatment.
The drug received orphan drug-designation from the FDA and EMA in May 2015, but it has yet to be approved in either region.
Upcoming Events
-
21Oct